BMC Infectious Diseases volume  22, Article number: 321 (2022 ) Cite this article

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide. Control of TB is lingering by the lack of diagnostic tests that are simple, rapid, yet accurate. Thus, smear-negative pulmonary TB often misses the diagnosis. The study evaluated the performance of GeneXpert MTB/RIF assay for the detection of Mycobacterium tuberculosis (MTB).

The study was carried out from June to December 2016 in Nepal Tuberculosis Center, Bhaktapur, Nepal. A total of 173 sputum samples were collected and processed by microscopy [Auramine-O staining and Ziehl–Neelsen (ZN) staining], followed by GeneXpert MTB/RIF assay and culture in Lowenstein-Jensen (LJ) medium.

Of 173 sputum samples, 162 (93.6%) were smear-negative. Of 162 smear-negative sputum samples, 35 (21.6%) were confirmed to have MTB by culture, and 31 (19.1%) by GeneXpert MTB/RIF assay. Of 31 GeneXpert-positive samples, 25 (80.6%) were susceptible, 4 (12.9%) were resistant, and 2 (6.45%) were intermediate to rifampicin. The sensitivity, specificity, positive predictive value, and negative predictive value of GeneXpert MTB/RIF assay for smear-negative sputum samples were 74.3%, 96.6%, 86.7%, and 92%, respectively. The GeneXpert MTB/RIF has a substantial diagnostic agreement of 90.91% with culture (Cohen’s Kappa coefficient = 0.73).

The diagnostic performance of GeneXpert MTB/RIF assay was almost on par with culture, and thus can be relied upon for MTB detection in smear-negative sputum samples.

Tuberculosis (TB), an infection caused by Mycobacterium tuberculosis (MTB), usually affects the lungs, but can also affect other parts of the body. Pulmonary TB (PTB) spreads easily by aerosols [1]. Globally, TB is a leading cause of death from a single infection. In 2019, there were an estimated 10 million new cases of TB, of which only 7 million cases were notified. Also, there were an estimated 1.4 million MTB attributed deaths. Similarly, there were an estimated 0.5 million new cases of rifampicin-resistant TB, of which 78% were multidrug-resistant TB (MDR-TB), but only 206,030 of MDR-TB were notified [2]. The lower efficacy of the diagnostic algorithm is one of the major reasons for lower notifications [2].

Sputum culture is the gold standard for the diagnosis of tuberculosis. However, it is expensive, contamination liable, labor-intensive, and time-consuming [3, 4]. This leads to delayed treatment and increased transmission [5]. Thus, early diagnosis plays a crucial role in the management and control of TB. Sputum smear microscopy is rapid and cheap, so is still used as the first-line technique for TB diagnosis, especially in resource-poor settings. But it lacks sensitivity (20–80%) and reproducibility [6, 7]. Therefore, employing an alternative rapid diagnostic tool is indispensable in the management of TB.

The GeneXpert MTB/RIF (Xpert) assay (Cepheid, Sunnyvale, CA, USA) is an automated nucleic acid amplification test. It can detect M. tuberculosis complex and rifampin resistance-associated mutation within two hours. In higher prevalence settings, Xpert has pooled sensitivity of 69.4- 84.7% and specificity of 98.4–98.8% [8, 9]; similarly, Xpert has pooled sensitivity of 60.6- 67% and a pooled specificity of 98.8% in smear-negative sputum samples [9, 10]. The technique is endorsed by the World Health Organization (WHO) as the point-of-care test for the diagnosis of both pulmonary and extra-pulmonary TB. However, full-fledged utilization of Xpert in low resource settings is challenging as it requires a constant electricity supply, a massive capital investment for devices and consumables, and persistent maintenance [11]. Nevertheless, with the subsidiary program from the global fund, Xpert testing is extensively being used in resource-limited settings with a higher TB burden. In Nepal, Xpert was first implemented in 2012 [12].

The poverty rate is high in Nepal [4], and poverty is a TB risk factor [6]. Almost half of the population in Nepal is presumed to have TB. In 2020, the total TB incidence was estimated to be 68,000, of which only 27,745 were notified, and TB attributed mortality was 17,220. This tantamount to 189 new cases, 101 missed cases, and 47 deaths every day [13]. The HIV-positive TB incidence in Nepal was 490, while HIV-positive TB mortality was 220 [13]. Since 2016, the nationwide ‘End TB Strategy’, has been implemented throughout the country. The treatment of TB is free of cost in Nepal. About NPR 1.8 billion (1 USD = NPR 118.5) were spent on TB in 2020 [13]. Still, the WHO recently enlisted Nepal in a group of 30 high MDR/RR- TB burden countries (MDR/RR-TB burden = 2,200) [13, 14]. Thus, on the premise of increasing TB prevalence in Nepal and the need for appropriate diagnostic algorithms, the study was conducted to assess the utility of Xpert for the rapid diagnosis of smear-negative TB in a high burden setting, Kathmandu in Nepal.

The hospital-based cross-sectional study was carried out in the National Tuberculosis Center (NTC), Bhaktapur (located on the Eastern side of Kathmandu Valley), Nepal from June to December 2016. NTC is the focal point of the national TB program in Nepal. NTC formulate policies, strategies, planning, monitoring, and quality assurance of TB programs. The Central Laboratory at NTC is responsible for planning, training, monitoring, supervision, evaluation, and quality control of the laboratory network in the country. NTC also provides diagnostic services for all types of presumptive TB for the people of Kathmandu Valley and the rest of the country. Kathmandu valley is a heavily dense setting with the capital city, Kathmandu. The population of the valley is around 2.5 million, but the actual figure is around 4 million. The population density is 2,793. For this study, the sample population was presumptive TB cases of all age groups and genders visiting the center. The presumptive TB cases were patients with symptoms or signs suggestive of TB i.e. productive cough for two or more weeks accompanied by one or more of the following symptoms: night sweats, loss of appetite, fever, unintentional weight loss, chest pain, shortness of breath, fatigue, and malaise. Patients were included in the study if their sputum samples were smear-negative. Patients already under treatment for PTB, or had previously confirmed TB (1–3 years prior), and those suspected of extra-pulmonary tuberculosis were excluded from the study.

A total of 173 sputum samples were collected from eligible patients. The patients were first counseled properly to produce a good sputum sample. Under supervision, two sputum samples were collected from each patient. For children and adults who were unable to expectorate sputum, sputum was induced using the nebulizer with hypertonic saline. The first specimen was collected on the spot and the second specimen was an early morning specimen of the next day (morning sample). The specimens were collected in a sterile, leak-proof, wide-mouthed, transparent plastic container (50 ml Falcon tube). The quality of the sputum sample was accessed macroscopically. The samples containing mostly saliva and nasal secretions were discarded and sample collection was repeated. The samples were well labeled and processed immediately or stored at 2 to 8ºC. The demographics of patients including age, sex, and smoking habits were also collected.

The sputum samples were observed microscopically for the presence of the Acid-Fast Bacilli (AFB) by auramine-O staining and Ziehl–Neelsen (ZN) staining [15]. If both specimens, i.e. spot and morning, from the same patient did not yield AFBs in both staining, then the sample was considered smear-negative. The smear-negative samples were further processed.

All the procedures for the Xpert assay were conducted as per the manufacturer’s instructions [16]. In brief, the sample reagent (mixture of NaOH and isopropanol) in the ratio of 1:2 was added to sputum samples in the Falcon tube. The mixture was vortexed thoroughly until the clear solution was seen and incubated at room temperature for 15 min to minimize biohazard by reducing the viability of M. tuberculosis. Then, 2 ml of clear solution was added to the labeled cartridge with the help of a sterile dropper and the cartridge was incubated inside the Xpert machine. Results were obtained in the Xpert system within 2 h. The samples yielding positive results in at least 1 of the 2 cartridges of 2 sputum specimens, i.e. spot and morning, in Xpert was considered as the Xpert-confirmed TB.

The sputum samples were digested and decontaminated by the modified Petroff method [17]. The digested sputum samples were inoculated on Lowenstein Jensen (LJ) media for culture. All the inoculated LJ media (slopes) were incubated at 37 °C for 8 weeks. The rough, buff, and tough growth of the LJ media was further subjected to ZN smear microscopy and biochemical tests to confirm M. tuberculosis [4]. M. tuberculosis was confirmed by their slow growth rate, colony morphology, inability to grow on LJ media containing p-nitrobenzoic acid (500 μg/ml), niacin test, and catalase test [4]. The samples yielding at least 1 of the 2 cultures of 2 sputum specimens, i.e. spot and morning, with M. tuberculosis growth was considered as the culture-confirmed TB. The culture-confirmed TB was considered as a definitive diagnosis.

All the generated data were entered and curated by using Microsoft Excel version 2016. The statistical analyses were performed by using R software version 4.1.1. A descriptive analysis was used to describe the demographic variables. Descriptive statistics were expressed as percentages. The contingency of the categorical variables was observed by using the chi-square (χ2) test. Pearson’s Phi-coefficient was used to measure the effect size among the variables. Phi-coefficient was interpreted using Cohen's rules-of-thumb. A p-value < 0.01 was considered statistically significant. Both culture and smear-negative samples were considered as true TB negative. And, using culture-confirmed TB as the reference standard, the efficacy of the Xpert was assessed against the culture by calculating the estimate of measures i.e. sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The estimates of measures were calculated using the formula as,

\({\text{NPV}} = {\text{d}}/\left( {{\text{c}} + {\text{d}}} \right)\) where, a = true positive, b = false positive, c = false negative and d = true negative.

The standard error (SE), the margin of error (M), and 95% Confidence Interval (CI) were calculated using the formula as,

\({\text{SE}} = {\text{square root }}\left[ {\left\{ {{\text{p}}*\left( {{1} - {\text{ p}}} \right)} \right\}/{\text{N}}} \right]\) where p is an estimate of measures and N = number of true values of samples as per the gold standard.

All the estimates were expressed in percentages. Similarly, Cohen's Kappa coefficient (κ) was used to measure the inter-rater agreement of Xpert with culture reports. Cohen’s Kappa coefficient was interpreted using Cohen’s criteria. Cohen’s criteria used were the values ≤ 0 as indicating no agreement, 0.01–0.20 as none to a slight agreement, 0.21–0.40 as fair agreement, 0.41–0.60 as moderate agreement, 0.61–0.80 as substantial agreement, and 0.81–1.00 as almost perfect to perfect agreement.

Of 173 presumptive TB patients, 162 (93.6%) were smear-negative, while 11 (6.4%) were smear-positive. Of these 162 smear-negative presumptive TB patients, 35 (21.60%) were culture positive for MTB, while Xpert only detected MTB in 31 (19.14%) cases. Besides, 4 (2.47%) were confirmed to have rifampicin-resistant MTB (Table 1).

The diagnostic performance of Xpert was almost similar to that of culture. There was no substantively significant association between Xpert assay and any of the demographics of patients (sex, age, smoking habits). Also, the same was the case for culture (Table 2).

Of 162 smear-negative samples, 9 were false negative and 5 were false positive in Xpert. Taking culture as a reference, Xpert showed high diagnostic performance. Xpert showed Cohen’s Kappa coefficient (κ) of 0.73 (i.e. substantial agreement). This implies 90.91% agreement of Xpert with culture (Table 3) (Table 4).

TB is a global public health threat, especially in the third world. Thus, early detection is of utmost importance for reducing deaths and transmission. Global TB control is hampered by the lack of rapid and accurate diagnostic tests.

Smear microscopy is a rapid and cheap method to detect AFB, but at least 5,000–10,000 bacilli per mL of sputum should be present in sputum to yield a positive report in smear microscopy. The fewer bacilli will yield a negative report in smear microscopy. Thus, it is less sensitive. The 3-day early morning sputum specimens are required to increase sensitivity. The infectious dose of TB is lower than 10 bacilli, thus, smear microscopy can easily miss such cases. The smear-negative cases often miss diagnostic algorithms in low-resource settings, like Nepal. The smear-negative, culture-positive TB patients account for about 13% of TB transmission. Smear microscopy fails to differentiate MTB from MTB complex [18, 19]. Culture is still the gold standard for TB detection. It has high sensitivity and can detect MTB when 10 viable bacilli per mL of sputum are present. But, culture demands a longer time extending up to 4 weeks. Also, culture requires a biosafety level 3 laboratory [20, 21].

This premise makes Xpert a very reliable alternative. Xpert can improve diagnosis in smear-negative and some culture-negative TB. The mucopurulent sputum increases the Xpert yield [22]. The performance of Xpert was almost similar to culture in smear-negative presumptive TB cases, irrespective of the demographics of patients and smoking habits. The sensitivity, specificity, PPV, and NPV of Xpert in reference to the culture method were higher. The high diagnostic performance of Xpert has also been reported elsewhere [8, 9, 23]. Kim et al. [24] also reported similar findings. Similarly, Gowda et al. [25] also reported similar sensitivity, specificity, and NPV, except PPV. The specificity of Xpert was high, 96.61%. This can be influenced by the presence of false-positive cases, i.e. Xpert-positive culture-negative cases. Also, molecular techniques, like Xpert, can detect the DNA of MTB (both viable and non-viable), while only viable cells can show growth in culture. So, Xpert-positive does not necessarily imply viable bacilli. Thus, Xpert should not be used to monitor response to treatment, treatment failure, or relapse [22, 26, 27]. Besides, such cases may receive unnecessary treatment and receive delayed appropriate treatment [28]. The negative reports of one or more specimens in Xpert, smear microscopy [29], or even culture [30] do not necessarily exclude PTB. The high NPV of Xpert signifies that it can play a crucial role in decision-making to reduce airborne isolation of hospitalized presumptive TB cases. Besides, Xpert was also shown to be the most cost-effective option [31].

Xpert also detects rifampicin resistance. But, Xpert had shown the variable sensitivity and specificity to detect rifampicin resistance. The variation might be attributed to the false-positive rifampicin-resistant strains due to the genomic mutation, exclusion of mixed infections, and the occurrence of both rifampicin resistance and susceptible MTB isolates in the same samples [32]. Rifampicin resistance was very low in this study, thus limiting the true evaluation of Xpert to detect rifampicin resistance. Also, we could not confirm the rifampicin resistance detected by Xpert using drug susceptibility testing. This is the limitation of this study that rifampicin-resistant and susceptible cases by Xpert were not further confirmed.

Xpert has been in use in Nepal since 2012. Very few studies have been done in small clusters, still, there is a lack of comprehensive study of Xpert performance in pragmatic conditions in Nepal. It is now crucial to conduct the cost–benefit analysis in pragmatic settings if a single Xpert is enough; as a second Xpert only seems important in HIV infection. With the increasing expense, high rates of non-diagnostic results and no improvement in the proportion of patients starting treatment in high burden regions have been reported [33,34,35]. However, the higher running and installation cost of the Xpert needs to be holistically measured with the benefit it provides by avoiding the poor sensitivity and specificity of smear microscopy.

Nevertheless, the more rapid and accurate assay, Xpert, can aid physicians to make better and more informed decisions for the management of presumptive TB cases. The findings of the study strongly suggest Xpert is a valuable inclusion to the TB armamentarium, as a rapid assay, which can be combined with clinical findings for the initial PTB therapeutic decisions. This in turn can provide advances in TB control campaigns.

The higher frequency of MTB in the smear-negative sputum sample signifies that authorities should keep eye on this domain for effective control of MTB. The diagnostic performance of the Xpert assay was almost on par with culture, and thus can be relied upon for MTB detection in smear-negative sputum samples.

First, the selection bias could have accounted for some errors in the findings. Second, the study was conducted for six months and the total samples were only 173. This is a comparatively small sample size. Thus, the generalization of the findings may not represent a real scenario. We believe that the research setting is the central TB laboratory of the country, so it represents the baseline scenario of the country as a whole. Even implying so, the larger sample population would give a better insight into the pragmatic diagnostic relevance of Xpert. Third, presumptive TB cases included in the study were not differentiated as per their severity. This could have affected the Xpert performance. Fourth, culture was used as the reference diagnostic test. Even though culture is still considered the gold standard, it too has limitations. Culture may also be falsely negative and if Xpert is positive, may not necessarily imply that the Xpert result is falsely-positive. Fifth, phenotypic drug susceptibility testing, line probe assay, and genotype MTBDRplus for all Xpert-positive specimens were not performed.

The complete dataset generated and analyzed during the study is already covered in the text. The raw data can be made available at reasonable request to the corresponding author.

World Health Organization (WHO): Tuberculosis. https://www.who.int/news-room/fact-sheets/detail/tuberculosis (2020). Accessed 12 Aug 2021.

World Health Organization (WHO): Global Tuberculosis Report 2020. 2020. https://www.who.int/publications/i/item/9789240013131.

World Health Organization (WHO): Tuberculosis diagnostics workshop: product development guidelines. Cleveland, Ohio; 1997. https://www.who.int/tdr/publications/documents/tuberculosis-diagnostics.pdf.

Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SS, Warnock DW. Manual of Clinical Microbiology. 11th ed. Washington: ASM Press; 2015.

William T, Parameswaran U, Lee WK, Yeo TW, Anstey NM, Ralph AP. Pulmonary tuberculosis in outpatients in Sabah, Malaysia: advanced disease but low incidence of HIV co-infection. BMC Infect Dis. 2015;15(1):32.

World Health Organization (WHO): Early detection of tuberculosis: an overview of approaches, guidelines and tools. 2011. https://apps.who.int/iris/handle/10665/70824.

Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(9):570–81.

Shapiro AE, Ross JM, Yao M, Schiller I, Kohli M, Dendukuri N, Steingart KR, Horne DJ. Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms. Cochrane Database Syst Rev. 2021. https://doi.org/10.1002/14651858.CD013694.pub2.

Article  PubMed  PubMed Central  Google Scholar 

Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, Ochodo EA, Haraka F, Zwerling AA, Pai M, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021. https://doi.org/10.1002/14651858.CD009593.pub5.

Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, Schumacher SG, Ochodo EA, Pai M, Steingart KR. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD009593.pub4.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization (WHO): Xpert MTB/RIF implementation manual: Technical and operational ‘how-to’: practical considerations. 2014. https://apps.who.int/iris/handle/10665/112469.

Nepal National Tuberculosis Program (NTP): Annual report 2016. 2016. https://nepalntp.gov.np/wp-content/uploads/2018/11/TB_Annual-Report-NTPN-2016-compressed.pdf.

Nepal National Tuberculosis Program (NTP): Tuberculosis profile 2076/77. 2020. https://nepalntp.gov.np/wp-content/uploads/2021/04/Factsheet_Final.pdf.

World Health Organization (WHO): WHO releases new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB. https://www.who.int/news/item/17-06-2021-who-releases-new-global-lists-of-high-burden-countries-for-tb-hiv-associated-tb-and-drug-resistant-tb (2021). Accessed 12 Aug 2021.

Jeyanathan M, Alexander DC, Turenne CY, Girard C, Behr MA. Evaluation of in situ methods used to detect Mycobacterium avium subsp. paratuberculosis in samples from patients with crohn’s disease. J Clin Microbiol. 2006;44(8):2942–50.

Cepheid: Xpert MTB/RIF. [Package insert]. Sunnyvale, CA: Cepheid. 2013.

Kent PT, Kubica GP: Public Health Mycobacteriology a guide for the level III laboratory. Centers for Disease Control Bureau of Laboratories, Centers for Disease Control; 1985: 21–44. https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB86216546.xhtml.

Riaz M, Mahmood Z, Javed MT, Javed I, Shahid M, Abbas M, Ehtisham-ul-Haque S. Drug resistant strains of Mycobacterium tuberculosis identified through PCR-RFLP from patients of Central Punjab, Pakistan. Int J Immunopathol Pharmacol. 2016;29(3):443–9.

Caulfield AJ, Wengenack NL. Diagnosis of active tuberculosis disease: from microscopy to molecular techniques. J Clin Tuberc Other Mycobact Dis. 2016;4:33–43.

Munir M, Rehman S, Aasim M, Iqbal R, Saeed S. Comparison of Ziehl Neelsen microscopy with GeneXpert for detection of Mycobacterium tuberculosis. IOSR-JDMS. 2015;14(11):56–60.

Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):111–5.

Acuña-Villaorduña C, Orikiriza P, Nyehangane D, White LF, Mwanga-Amumpaire J, Kim S, Bonnet M, Fennelly KP, Boum Y, Jones-López EC. Effect of previous treatment and sputum quality on diagnostic accuracy of Xpert® MTB/RIF. Int J Tuberc Lung Dis. 2017;21(4):389–97.

Li S, Liu B, Peng M, Chen M, Yin W, Tang H, Luo Y, Hu P, Ren H. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: A systematic review and meta-analysis. PLoS ONE. 2017;12(7):e0180725.

Kim C-H, Woo H, Hyun IG, Kim C, Choi J-H, Jang S-H, Park SM, Kim D-G, Lee MG, Jung K-S, et al. A comparison between the efficiency of the Xpert MTB/RIF assay and nested PCR in identifying Mycobacterium tuberculosis during routine clinical practice. J Thorac Dis. 2014;6(6):625–31.

PubMed  PubMed Central  Google Scholar 

Gowda NC, Ray A, Soneja M, Khanna A, Sinha S. Evaluation of Xpert®Mycobacterium tuberculosis/rifampin in sputum-smear negative and sputum-scarce patients with pulmonary tuberculosis using bronchoalveolar lavage fluid. Lung India. 2018;35(4):295–300.

Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13(4):349–61.

Kennedy N, Gillespie SH, Saruni AOS, Kisyombe G, McNerney R, Ngowi FI, Wilson S. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. J Infect Dis. 1994;170(3):713–6.

Costantini L, Marando M, Gianella P. Long-term genexpert positivity after treatment for pulmonary tuberculosis. EJCRIM. 2020. https://doi.org/10.1016/j.chest.2020.05.117.

Article  PubMed  PubMed Central  Google Scholar 

Shah NS, Cavanaugh JS, Pratt R, Cain KP, Wells C, Laserson K, Nelson L. Epidemiology of smear-negative pulmonary tuberculosis in the United States, 1993–2008. Int J Tuberc Lung Dis. 2012;16(9):1234–40.

Dutt AK, Moers D, Stead WW. Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy. Am Rev Respir Dis. 1989;139(4):867–70.

Cowan JF, Chandler AS, Kracen E, Park DR, Wallis CK, Liu E, Song C, Persing DH, Fang FC. Clinical impact and cost-effectiveness of Xpert MTB/RIF testing in hospitalized patients with presumptive pulmonary tuberculosis in the United States. Clin Infect Dis. 2017;64(4):482–9.

Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, Collman RG, Klausner JD, Modongo C, Land GA. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by genexpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol. 2014;52(7):2422–9.

Monedero-Recuero I. Xpert implementation in challenging scenarios: a brand-new car running on the same bumpy old roads. Public Health Action. 2018;8(1):1–1.

Hanrahan CF, Haguma P, Ochom E, Kinera I, Cobelens F, Cattamanchi A, Davis L, Katamba A, Dowdy D. Implementation of Xpert MTB/RIF in Uganda: missed opportunities to improve diagnosis of tuberculosis. Open Forum Infect Dis. 2016. https://doi.org/10.1093/ofid/ofw068.

Article  PubMed  PubMed Central  Google Scholar 

Vassall A, Siapka M, Foster N, Cunnama L, Ramma L, Fielding K, McCarthy K, Churchyard G, Grant A, Sinanovic E. Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. Lancet Glob Health. 2017;5(7):e710–9.

We are indebted to the National Tuberculosis Center (NTC), Bhaktapur, Nepal for kind cooperation and support.

Department of Microbiology, Shi-Gan International College of Science and Technology, Kathmandu, Nepal

Raksha Rimal, Dhiraj Shrestha, Susil Pyakurel, Rashmi Poudel & Ganesh Rai

Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences, Fujian Agriculture and Forestry University, Fuzhou, China

Prasha Shrestha & Kul Raj Rai

National Tuberculosis Center, Bhaktapur, Nepal

Department of Microbiology, Nepal Medical College and Teaching Hospital, Kathmandu, Nepal

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

RR, PS, and DS conceptualized and designed the study methodology. RR and RP performed laboratory investigations. RR, SP, and PS collected data, analyzed data, reviewed literature, prepared, and edited the draft of the manuscript. KRR, GRG, GR, SKR, and DS supervised the entire project and edited the manuscript. DS performed data analysis and prepared the final version of the manuscript. All authors read and approved the final manuscript.

This research was approved by Shi-Gan Institutional Review Committee Kathmandu, Nepal. Written informed consent is not feasible for all subjects in the Nepalese context as illiteracy is comparatively higher. Thus, to reduce selection bias, written informed consent was obtained from the literate participants while verbal informed consent was obtained from illiterate participants in presence of a lab personnel. In case of children, consent was obtained from parents/guardians on their behalf, as approved by the ethical review committee.

The authors declare that they have no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Rimal, R., Shrestha, D., Pyakurel, S. et al. Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients. BMC Infect Dis 22, 321 (2022). https://doi.org/10.1186/s12879-022-07287-5

DOI: https://doi.org/10.1186/s12879-022-07287-5

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

By using this website, you agree to our Terms and Conditions, California Privacy Statement, Privacy statement and Cookies policy. Manage cookies/Do not sell my data we use in the preference centre.

© 2022 BioMed Central Ltd unless otherwise stated. Part of Springer Nature.